A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension

被引:1
|
作者
Lui, Justin K. [1 ]
Gillmeyer, Kari R. [1 ]
Sangani, Ruchika A. [1 ]
Smyth, Robert J. [1 ]
Gopal, Deepa M. [2 ]
Trojanowski, Marcin A. [3 ]
Bujor, Andreea M. [3 ]
Wiener, Renda Soylemez [1 ,4 ]
Lavalley, Michael P. [3 ,5 ]
Klings, Elizabeth S. [1 ]
机构
[1] Boston Univ, Pulm Ctr, Chobanian & Avedisian Sch Med, 72 East Concord St,R-304, Boston, MA 02118 USA
[2] Boston Univ, Chobanian & Avedisian Sch Med, Sect Cardiovasc Med, Boston, MA USA
[3] Boston Univ, Chobanian & Avedisian Sch Med, Sect Rheumatol, Boston, MA USA
[4] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA
[5] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
关键词
Clinical prediction rule; Connective tissue disease; Diffuse scleroderma; Limited scleroderma; Pulmonary function test; Pulmonary artery; PRESSURE;
D O I
10.1007/s00408-023-00646-2
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
We devised a scoring system to identify patients with systemic sclerosis (SSc) at risk for pulmonary hypertension (PH) and predict all-cause mortality. Using 7 variables obtained via pulmonary function testing, echocardiography, and computed tomographic chest imaging, we applied the score to a retrospective cohort of 117 patients with SSc. There were 60 (51.3%) who were diagnosed with PH by right heart catheterization. Using a scoring threshold >= 0, our decision tool predicted PH with a sensitivity, specificity, and accuracy of 0.87 (95% CI 0.75, 0.94), 0.74 (95% CI 0.60, 0.84), and 0.80 (95% CI 0.72, 0.87), respectively. When adjusted for age at PH diagnosis, sex, and receipt of pulmonary arterial vasodilators, each one-point score increase was associated with an adjusted HR of 1.19 (95% CI 1.05, 1.34) for all-cause mortality. With further validation in external cohorts, our simplified clinical decision tool may better streamline earlier detection of PH in SSc.
引用
下载
收藏
页码:565 / 569
页数:5
相关论文
共 50 条
  • [1] A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension
    Justin K. Lui
    Kari R. Gillmeyer
    Ruchika A. Sangani
    Robert J. Smyth
    Deepa M. Gopal
    Marcin A. Trojanowski
    Andreea M. Bujor
    Renda Soylemez Wiener
    Michael P. LaValley
    Elizabeth S. Klings
    Lung, 2023, 201 : 565 - 569
  • [2] The clinical characteristics of systemic sclerosis-related pulmonary arterial hypertension
    王辉
    China Medical Abstracts (Internal Medicine), 2014, 31 (03) : 154 - 154
  • [3] Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension
    Dimitroulas, Theodoros
    Giannakoulas, Georgios
    Karvounis, Haralambos
    Sfetsios, Tilemahos
    Koliakos, Georgios
    Parcharidis, Georgios
    Settas, Loucas
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 121 (01) : 135 - 137
  • [4] Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?
    Nikpour, M.
    Stevens, W.
    Proudman, S. M.
    Buchbinder, R.
    Prior, D.
    Zochling, J.
    Williams, T.
    Gabbay, E.
    Nandurkar, H.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (05) : 599 - 603
  • [5] Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension
    Dimitroulas, T.
    Sfetsios, T.
    Pliakos, C.
    Giannakoulas, G.
    Koliakos, G.
    Dimitroula, H.
    Settas, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 389 - 390
  • [6] Biomarkers in Systemic Sclerosis-Related Pulmonary Arterial Hypertension
    Dimitroulas, Theodoros
    Giannakoulas, Georgios
    Karvounis, Haralambos
    Settas, Loukas
    Kitas, George D.
    CURRENT VASCULAR PHARMACOLOGY, 2011, 9 (02) : 213 - 219
  • [7] CONVENTIONAL ECHOCARDIOGRAPHIC FINDINGS IN SYSTEMIC SCLEROSIS-RELATED PULMONARY HYPERTENSION
    Lui, Justin
    Sangani, Ruchika
    Martin, Brett
    Bujor, Andreea
    Trojanowski, Marcin
    Gopal, Deepa
    Wiener, Renda
    Klings, Elizabeth
    CHEST, 2020, 158 (04) : 2181A - 2182A
  • [8] Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension
    Dimitroulas, T.
    Giannakoulas, G.
    Sfetsios, T.
    Karvounis, H.
    Dimitroula, H.
    Koliakos, G.
    Settas, L.
    RHEUMATOLOGY, 2008, 47 (11) : 1682 - 1685
  • [9] Natriuretic Peptides in Systemic Sclerosis-related Pulmonary Arterial Hypertension
    Dimitroulas, Theodoros
    Giannakoulas, Georgios
    Karvounis, Haralambos
    Gatzoulis, Michael A.
    Settas, Loucas
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 39 (04) : 278 - 284
  • [10] Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA
    Ratanawatkul, Pailin
    Solomon, Joshua J.
    Kim, Darlene
    George, Marjorie P.
    McGibbon, Lia R. Matarrese
    Demoruelle, M. Kristen
    Maleki-Fischbach, Mehrnaz
    Amigues, Isabelle
    Kastsianok, Liudmila
    Perez, Evans R. Fernandez
    ERJ OPEN RESEARCH, 2020, 6 (02) : 1 - 8